Loading...
Loading...
The company has seen two positive estimate revisions in the past 30 days, while its Zacks Consensus Estimate moved higher over the same time frame, suggesting more solid trading ahead. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Conatus Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Other better-ranked medical stocks worth considering include Cardica Inc. CRDC, ICU Medical, Inc. ICUI and NeuroMetrix Inc. NURO. All these stocks have a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free reportCONATUS PHARMA CNAT: Free Stock Analysis Report
CARDICA INC CRDC: Free Stock Analysis Report
ICU MEDICAL INC ICUI: Free Stock Analysis Report
NEUROMETRIX INC NURO: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in